Healthpeak Properties, Inc. (NYSE: DOC) — A Cheap Three-Legged Healthcare Landlord Arbitraging Its Own Multiple While Its Worst Leg Bottoms

Independent equity research and general information — not investment advice. The analysis body (Sections 1–15) is written position-free and carries no price target; the single exception is the clearly-labeled “Author’s Take” opinion block below.

As of: 2026-07-11 · Price: $21.65 (2026-07-10 close) · Shares (common): ~695M · Equity mkt cap: ~$15.0B · Net debt: ~$9.4B · Enterprise value: ~$24.5B · 2026 FFO-adj guide: $1.71–$1.75 · Dividend: $1.22 (monthly) · Yield: ~5.6% · Net debt/EBITDAre: ~5.2–5.4x · Ratings: Baa1 / BBB+

⚡ Author’s Take

This block is the author’s own subjective opinion. It is not investment advice. Everything below it (Sections 1–15) is written position-free and carries no recommendation and no price target.

Verdict: HOLD — a fairly-priced, well-run, diversified investment-grade healthcare REIT whose worst business is bottoming and whose best business it just sold to the public at 30x. Accumulate on weakness toward $18–19 (≈10.5–11x FFO, ~1.7x tangible book, ~6.4% yield); trim into $24–25 (≈14x). At $21.65 it is roughly fair — the easy money was made off the December low. Conviction: medium. Framing: rate-sensitive value / mean-reversion, not momentum — and emphatically not a compounder.

Healthpeak is three businesses in three different places in the capital cycle: an excellent, low-cost medical-outpatient platform (52% of NOI, the ballast); a beaten-down but bottoming life-science/lab portfolio (37% of NOI, the swing factor and the option); and a small, fast-growing senior-housing stake it IPO’d in March 2026 as Janus Living (NYSE: JAN), retaining 81.6% and pocketing a ~30x-AFFO public mark on NOI it couldn’t get credit for inside the conglomerate. The Janus trade is clever financial engineering — it reveals value, it doesn’t create NOI — and its payoff hinges on the public continuing to pay a senior-housing premium DOC still owns 81.6% of the downside to. The stock’s 37% rip off the December-2025 low is not a quality re-rating; the factor tape flags it as a rate-recovery value bounce (InterestRate beta −0.53, Value +0.20, Growth −0.40, Momentum −0.16) off a name that was left for dead. What keeps me at HOLD rather than constructive: 2026 FFO/share is guided down ~6% (rising debt cost + lab occupancy erosion + dilutive-though-accretive asset recycling), lab same-store NOI has swung from +5% to −7.2% in five quarters, and — most telling — with the CEO loudly declaring the stock trades below NAV and buying back $100M of it, not a single insider bought a share in the open market in two years. Smart capital allocation (sell stabilized assets at ~6% caps, buy your own stock at a ~10% AFFO yield) is real and NAV-accretive; it just isn’t a growth engine. This is a 5.6%-yielding bond-plus-optionality on a lab recovery and lower rates — own it for income and the trough call, not for compounding.

• What flips me bullish: lab same-store NOI inflects positive on confirmed net absorption (the 2.5M sf of vacant “latent earnings” leasing up) and biotech funding/IPO issuance durably reopens — turning the 37%-of-NOI drag into a tailwind while the MOB annuity and Janus premium hold. That would make ~$2.00+ FFO/share visible into 2027–28 and re-rate the stub.
• What flips me bearish: lab keeps bleeding (SS NOI stays negative, occupancy breaks below ~88%) as NIH cuts and the supply glut bite, or long rates back up and JAN de-rates toward senior-housing-peer multiples — collapsing the arbitrage DOC still owns 81.6% of, and exposing a diversified REIT with no wide moat, thin insider skin, and flat-to-down near-term earnings.

Tag: “Three legs, three cycles — renting the market a higher multiple on the one leg it kept.”

📈 Stock Price Action — Five-Year Event Map

DOC (the surviving Healthpeak entity, formerly HCP) round-tripped a full cycle: from a life-science-boom peak of ~$37 (Aug 2021) down to a rate-and-lab-bust low of ~$15.55 (Oct 2023), a post-merger bounce to ~$23 (Oct 2024), a grind back to ~$15.78 (Dec 2025), and a sharp ~37% rally to ~$21.93 (Jul 2026) on the Janus Living IPO and rate-cut hopes. It sits today at $21.65, roughly the middle of a ~$15.78–$21.93 52-week range and ~42% below its 2021 high — a stock that has been dead money for five years (5-yr annualized total return ≈ −1%) now in the early innings of a mean-reversion recovery.

Cycle narrative. (1) The 2021 melt-up was the life-science bubble — DOC’s lab franchise was its most-prized asset and the market paid a growth multiple for it. (2)–(3) The 2022–23 collapse was two blows at once: a classic rate shock hitting all long-duration REITs, and a dawning realization that the 2020–21 lab construction boom would flood the big clusters with vacancy. The October-2023 Physicians Realty merger announcement added a deal overhang. (4) 2024 was the recovery of a completed, accretive merger — the MOB platform’s stability and scale re-rated the stock. (5) 2025 gave it all back as lab occupancy visibly cracked (same-store lab NOI decelerating toward negative), rates stayed high, and NIH-funding cuts loomed. (6) The 2026 rally is the Janus Living IPO catalyst plus rate-cut positioning — a rate-sensitive value name (InterestRate factor loading −0.53) mean-reverting off a washed-out base, not a fundamentals-led compounding run. The price move is Fact; the attribution is Interpretation, cross-referenced to earnings dates, the merger 8-Ks, the Janus IPO, and the rate/biotech macro backdrop.

1. Executive Summary

Healthpeak Properties is the third-largest U.S. healthcare REIT and the only one with material exposure to all three principal healthcare-property types: medical outpatient buildings (MOB), life-science/lab, and senior housing. The company was created in its current form by the March-2024 all-stock merger of Healthpeak (fka HCP, itself an S&P 500 REIT dating to a 1985 spin) and Physicians Realty Trust — which is why the surviving entity trades under Physicians Realty’s old ticker, DOC. It owns ~50 million square feet, carries ~$24.5B of enterprise value, and generates ~$1.54B of annual segment NOI split roughly 52% outpatient / 37% lab / 11% senior housing.

The investment tension is a diversified, investment-grade landlord priced in the cheap half of the healthcare-REIT complex (~12.5x forward FFO, ~5.6% yield) precisely because its second-largest business — the life-science portfolio it once regarded as the crown jewel — is in the trough of a violent capital cycle. National lab vacancy is ~23%, DOC’s own same-store lab NOI has swung from +5% to −7.2% year-over-year in five quarters, and a July-2026 federal budget cut ~$18B of NIH funding into 2026. Offsetting this: the MOB business is a genuinely well-run, low-leasing-cost annuity throwing off +3.8% same-store NOI at 92% occupancy, and the senior-housing business is growing double-digits into a powerful demographic wave.

Management’s headline 2026 move was to IPO the senior-housing arm as Janus Living (NYSE: JAN) in March 2026, selling ~18% to the public while retaining 81.6% and installing itself as external manager. Because DOC still consolidates Janus, this is not deleveraging and not a realized gain — it is a multiple-arbitrage maneuver: the public pays ~25–30x AFFO for senior-housing NOI that the market would not credit inside a diversified REIT trading at low-teens FFO. The maneuver is clever and, on paper, NAV-accretive, but it creates real value only so long as the public keeps paying the premium, and it introduces related-party governance friction that both the 10-K and proxy flag.

Financially, the story is honest but going the wrong way near-term. Earnings quality is above-average for the sector: only ~6% of FFO is non-cash straight-line/above-market rent (medical-office leases are short, so no phantom-rent build), AFFO is a healthy ~92% of FFO-adjusted, the dividend is well-covered at a ~72% AFFO payout, and the balance sheet is solidly investment-grade (5.2–5.4x net debt/EBITDAre, 88% fixed-rate, $3.0B revolver undrawn). But 2026 FFO-adjusted per share is guided down ~6% to $1.71–$1.75 versus $1.84 in 2025 — the combined drag of refinancing 3.4–4.0% debt into 4.75–5.375% coupons, lab occupancy erosion, disposition dilution, and the new 18.4% Janus minority leakage.

Capital allocation is the genuinely impressive part — and the clearest signal of management’s own NAV view. DOC is selling stabilized outpatient assets to Blackstone at a 6.1% cap rate and buying back its own stock at a ~10%+ AFFO yield (a ~$100M repurchase in April 2026 at ~$16.81). That is textbook value-accretive recycling. Yet the same management team that argues publicly the stock trades below intrinsic value bought exactly zero shares in the open market across 96 insider filings in 2024–2026 — a neutral-to-soft personal signal that sits awkwardly beside the corporate buyback.

DOC has no wide moat. Its durable edge is narrow and real: an in-house medical-office leasing and property-management platform (internalized in the Physicians Realty merger, now delivering >$65M of synergies) that produces below-peer leasing costs, and decades-long health-system relationships that create genuine switching costs on-campus. But it is sub-scale in the best sub-sector (senior housing), over-exposed (though far less than pure-play Alexandria) to the worst (lab), and diversified in a way that smooths the cycle while diluting the multiple. It is a fairly-valued income-and-optionality vehicle, not a compounder.

2. Business Overview

Healthpeak owns, operates, develops, and manages real estate serving what it calls “healthcare discovery and delivery.” Following the Physicians Realty merger, the portfolio is organized into three reportable segments plus a small other/loans book. Revenue is overwhelmingly rental income from long-lived real estate, predominantly under triple-net or effectively-net leases with contractual annual escalators (~3% in outpatient; ~89% of lab is net) — a recurring, contractual revenue base with modest but real mark-to-market on renewal.

Segment mix (FY2025 total-portfolio Adjusted NOI ≈ $1,540M):

Outpatient Medical is the ballast: ~40 million square feet of medical office, the vast majority on or adjacent to hospital campuses, leased to health systems (top tenants HCA ~15% of segment revenue / ~7% of total; CommonSpirit ~6%/3%) and physician groups on long, escalating, net leases. Nine on-campus hospitals are 100% triple-net. Care continues shifting from inpatient to ambulatory settings, and hospital tenants value proximity — giving this segment genuine, if modest, switching costs and the sector’s most stable cash flow.

Lab/Life Science is the higher-beta, higher-rent portfolio, deliberately concentrated in the three premier U.S. clusters — South San Francisco, Cambridge/Boston, and San Diego — plus a handful of submarkets management says can be toured “in a single day.” Rents run ~$60/sf triple-net (headline) to ~$91/occupied sf (all-in), tenants range from venture-backed biotech to large-cap pharma (e.g., Genentech at 751 Gateway to 2034), and the buildings are physically specialized wet-lab space. This is the segment in the cycle’s crosshairs.

Senior Housing is now legally a separate public company, Janus Living (NYSE: JAN), of which DOC owns 81.6% and which it manages externally. These are RIDEA-structured communities (DOC/JAN takes operating upside and downside via a manager, rather than a fixed lease) plus continuing-care retirement communities (CCRCs) with entrance-fee economics. Because DOC consolidates JAN, all of Janus’s revenue, assets, and debt still appear on DOC’s statements, with an 18.4% noncontrolling-interest deduction below the line.

Verdict: A genuinely diversified, recurring-revenue healthcare landlord — the only large one spanning all three property types. The diversification is real and lowers cyclical variance, but it also means no single premium growth engine drives the multiple.

3. Industry Dynamics

DOC’s three legs sit in three distinct places in Marathon’s capital cycle, and that dispersion is the industry story.

Life-science/lab — a textbook capital-cycle bust, cyclically bottoming. The 2020–21 biotech boom drew a flood of capital and construction; annual U.S. lab deliveries roughly tripled to ~14.5M sf by 2025, and of the ~60M sf delivered 2020–2025, ~55.6% sits vacant. National lab vacancy is ~23–23.5% (Q1 2026); the big-three clusters (~130M sf combined) run above 30% vacancy, and Boston asking rents broke below $80/sf for the first time since 2022. Two demand overhangs compound the supply glut: the biotech funding/IPO cycle only began reopening in 2026 (IPOs fell 93→26→10 across 2021/24/25), and the One Big Beautiful Bill Act (signed July 4, 2026) cut NIH funding ~$18B to $27.5B for 2026 — a direct hit to early-stage lab demand. The bellwether, Alexandria (ARE), cut its dividend ~45% and reported a quarter with zero public-biotech leases. The bottoming signals are nonetheless real: new starts have collapsed, availability across the top-12 markets contracted ~2M sf over nine months, and vacancy is expected to plateau at a cyclical peak in 2026. This is DOC’s least attractive leg — and where the option value sits.

Medical outpatient — the disciplined quadrant. MOB occupancy hit a record ~92.7% in 2026, with 42 of 125 markets above 95%. New construction starts bottomed in late 2024 at the lowest level in roughly two decades, so absorption outpaces deliveries and landlords hold pricing power. Demand is secular and need-based: the shift of procedures to ambulatory settings plus an aging population (65+ growing ~3.1%/yr), anchored by creditworthy health-system tenants signing lengthening terms. Growth is modest (same-store NOI ~2–5%) but this is the most bond-like healthcare property type.

Senior housing — the demographic tailwind (but DOC is a partial participant). The 80+ population grows ~55% by 2035 on a fixed clock; industry occupancy has recovered to ~89.5% across 19 consecutive up-quarters, while NIC primary-market inventory growth (+0.4%) is the lowest on record with virtually nothing new opening before 2027–28. Supply/demand is the most favorable of the three — which is exactly why capital (~$24B/yr of transactions) is flooding back and compressing cap rates. This is the WELL/VTR home turf; DOC largely exited after 2020 and is a late, sub-scale re-entrant via the Janus vehicle.

Verdict: Two structurally good industries (outpatient, senior housing) and one structurally challenged but cyclically bottoming (lab). On a blended basis, a structurally acceptable industry mix — the outpatient and senior-housing tailwinds are durable; the lab overhang is severe but self-correcting on the supply side.

4. Competitive Position

Name the moat: there isn’t a wide one. In Greenwald’s taxonomy, DOC has (a) modest economies of scale (~50M sf, national platform), (b) a cost-of-capital advantage versus private and sub-scale owners (investment-grade, $3B revolver, public equity), and © a narrow but genuine operational edge in medical outpatient — none of which individually constitutes a durable, wide moat.

The real, demonstrable advantage is the in-house MOB leasing and property-management platform internalized in the Physicians Realty merger. DOC now does roughly half its outpatient renewals in-house (saving ~$5M of leasing commissions in a single quarter), turns leases at ~10% of annual rent in leasing costs (well below peers), and consequently books stronger net effective rents and superior cash conversion. Over the trailing five years its outpatient same-store NOI has averaged +3.5% — ~30% higher than the prior five-year average. Combined with on-campus, health-system-affiliated locations (96% of the MOB book), this produces real switching costs: a hospital’s physicians do not casually relocate off-campus. That is a defensible, if narrow, franchise — the closest thing DOC has to a moat, and it applies to only ~52% of NOI.

In life science, DOC’s strategy is deliberate concentration — dominating the broker networks and tenant flow in a few premier submarkets rather than diversifying into secondary markets. That concentration was an asset in the boom and is a liability mid-bust, but management’s discipline (it “shut off capital allocation way before anybody else” in 2021) means it avoided the worst of the oversupply and is now buying distressed assets — e.g., the Gateway South SF campus at “a small fraction of replacement cost.” Still, in a market with 23% vacancy, being a good operator of specialized space is not a moat; it is damage control with option value.

Versus peers: DOC is inferior to WELL and VTR on the best sub-sector — it has almost no senior-housing operating scale, only the Janus stake and a management fee. It is roughly peer-equal to Healthcare Realty (HR) on outpatient — both ~5.5x levered, ~11–12x FFO — though HR is the cleaner MOB pure-play and DOC the more diversified, lower-single-segment-risk name. It is better-diversified and lower-risk than Alexandria (ARE), whose undiluted life-science bet forced a 45% dividend cut; DOC’s outpatient and senior-housing legs cushion the lab drag that hits ARE full-force. DOC’s genuine distinction is being the only large healthcare REIT exposed to all three property types — diversification that smooths the cycle but dilutes the moat and caps the multiple.

Verdict: A diversified, investment-grade, no-wide-moat healthcare REIT with a narrow, real operating advantage in medical outpatient, sub-scale in the best segment and over-exposed (though far less than ARE) to the worst. Crowded, competitive markets with modest differentiation — not a franchise business.

5. Growth History and Forward Opportunities

History. Revenue grew from $1.64B (2020) to $2.82B (2025), but the bulk of the jump is the March-2024 Physicians Realty merger (2023 $2.18B → 2024 $2.70B), not organic compounding. On a per-share basis, FFO-adjusted has been flat-to-slightly-up: ~$1.78 (2023) → ~$1.80 (2024) → $1.84 (2025) — and is now guided down to $1.71–$1.75 for 2026. This is not a growth stock; it is an income vehicle with a cyclical swing factor.

Same-store NOI tells the real operating story by segment:

Forward opportunities:

• Lab lease-up = latent earnings. DOC has ~2.5M sf of vacant lab space producing no income (and some carrying drag). Management targets year-end 2026 lab occupancy up ≥100bps, with ~0.5M sf of signed-but-not-commenced leases more than offsetting ~0.4M sf of 2026 expirations, and a ~2M sf active pipeline. If biotech funding durably reopens (April 2026 was the busiest biotech equity-issuance month since early 2021), this segment flips from drag to tailwind into 2027–28.
• Gateway South San Francisco (~$559M, Dec-2025/Jan-2026). A “once-in-a-decade,” fraction-of-replacement-cost acquisition of a 1.4M sf / 29-acre campus (~60% occupied, Genentech anchor), already leasing ahead of underwriting. Contributes little to 2026 but is the clearest 2027+ upside lever.
• Blackstone outpatient JV as a funding template. DOC recapitalized six outpatient buildings with Blackstone at a 6.1% cap rate ($163M net proceeds), and flags $700M+ more of similar recaps/acquisitions — a low-cost-of-capital source cheaper than issuing its own public equity.
• Health-system MOB development (highly pre-leased, e.g., Northside Hospital Atlanta) and the ~5M sf mixed-use Alewife/Cambridge project (half multifamily, with Hines) — long-dated optionality, groundbreaking not before 2027.
• Senior-housing growth via Janus — RIDEA occupancy/rate recovery plus accretive acquisitions using JAN’s premium currency, 81.6% of which accrues to DOC.

Verdict: Low-quality growth today, latent higher-quality growth tomorrow. Near-term, growth is negative (2026 FFO/share down ~6%) as lab and refinancing bite. The forward opportunity is real but optional — it depends on a lab recovery and lower rates that are not yet in the numbers.

6. Financial Quality

Earnings quality is above-average for the sector. GAAP EPS ($0.10 in 2025) is meaningless here — it reflects $1.06B of real-estate depreciation add-backs, so FFO is ~18x net income by construction, which is normal for a REIT. The meaningful metrics:

Quality-of-earnings checks — mostly clean:

• Low non-cash content. The only non-cash “revenue” backed out to reach AFFO is straight-line rent (~$39.2M) plus above/below-market lease amortization (~$36.7M) — together ~$76M, only ~5.9% of FFO-adjusted. Because medical-office leases are short, DOC has no large phantom straight-line-rent build (the SL receivable isn’t even separately disclosed) — a favorable contrast to net-lease REITs.
• AFFO = ~92% of FFO-adjusted — a healthy, small gap. Recurring/second-generation AFFO capex (~$134M, up from ~$116M) is a real ~10% cash drag, honestly deducted.
• Margins: EBITDA margin steady ~55%; gross margin ~60%. Stable, as expected for a landlord.

The red flag is direction, not quality. Q1 2026 FFO-adjusted fell −3.9% year-over-year, Nareit FFO −6.8%, and full-year 2026 guidance sits ~6% below 2025. The Q1 GAAP EPS jump ($0.28 vs $0.06) is non-recurring gains ($92M Blackstone deconsolidation + $46M SWF), not operating strength — exclude them from run-rate. ROIC/ROE from aggregators are not usable for a REIT (depreciation distorts the denominator and numerator); the economically relevant return is the ~6.5–7% implied cap rate on gross assets and the ~10%+ AFFO yield at the current stock price.

Balance sheet and debt structure. DOC carries ~$9.85B of total debt against ~$24.5B of enterprise value — leverage that is comfortable and squarely investment-grade (Baa1 / BBB+), a genuine differentiator versus private lab owners now “totally upside down” (management’s words) in the downturn. The composition is defensive: ~88% fixed-rate (down from 97% only because commercial paper grew), a weighted-average effective coupon ~4.2%, ~$6.8B of senior unsecured notes, ~$1.65B of term loans (swapped to fixed at 3.76–4.66%), ~$1.08B of commercial paper (revolver-backstopped), and only ~$349M of mortgage debt. Liquidity is ample: a $3.0B revolver undrawn to January 2029, $2.0B of CP capacity, ~$467M cash, and a fresh $400M 2031 delayed-draw term loan sitting undrawn as dry powder.

The one clear negative embedded here is the cost-of-debt reset: DOC refinanced ~$800M of 3.40–4.00% maturities in 2025 with ~$1.0B of 4.75–5.375% notes, and the ~$650M of 3.5% notes maturing in June 2026 will reprice similarly. Each turn of refinancing at ~100–150bp higher coupons is a direct, structural FFO headwind — a meaningful chunk of the ~6% 2026 earnings decline is simply higher interest expense, not operating deterioration. Net debt/EBITDAre of ~5.2–5.4x is mid-pack for the sector (below VTR/HR-comparable, above the A-rated Welltower) and leaves the balance sheet with capacity but no urgency to delever.

Verdict: Economics are stable and honestly reported, but they are not improving with scale right now — 2026 earnings decline modestly on a rising cost of debt and lab softness, atop an investment-grade, well-laddered balance sheet. High-quality accounting on a cyclically soft year.

7. Capital Allocation

This is the section where DOC scores best — and where the one behavioral tell sits.

The NAV-accretive recycling arbitrage (intelligent). DOC is systematically selling stabilized assets to private buyers at low-6% cap rates and redeploying into (a) buying back its own stock at a ~10%+ AFFO yield and (b) distressed/opportunistic acquisitions at fractions of replacement cost. The Blackstone JV sold 80% of six outpatient buildings at a 6.1% cap ($163M net); 2025 dispositions totaled ~$346M of outpatient at similarly tight caps. Meanwhile DOC repurchased ~$94M of stock in 2025 (~$18.50) and ~$100M in April 2026 (~$16.81), with ~$306M remaining on the authorization. Selling at a 6% cap and buying your own equity at a ~10% yield is directly accretive to NAV per share — this is disciplined, value-first capital allocation, and it is management’s clearest revealed view that the stock trades below intrinsic value.

The Janus Living IPO (clever, but engineering not creation). In March 2026 DOC IPO’d its senior-housing arm as Janus Living (NYSE: JAN), selling ~18% (48.3M shares at $20 = $966M gross, ~$880M net) while retaining 81.6% and acting as external manager (~$10M base fee + 0.5% of gross-book-value growth). JAN opened ~$23.50 and trades at ~25–30x AFFO versus DOC’s low-teens — the ~20-turn “multiple arbitrage” the CEO cites, forcing the market to mark ~$4.25B+ of senior-housing value versus ~$3B book. Proceeds fund ~$750M of accretive senior-housing acquisitions. Correctly understood, this is value revelation, not value creation: DOC still consolidates JAN and owns 81.6% of the downside; the gain is real only if the public keeps paying a senior-housing premium. It also introduces related-party governance friction (overlapping boards, a manager conflict) flagged in the 10-K and proxy.

Dividend: $1.22/share, switched to monthly in April 2025, ~72% AFFO payout — well-covered, no cut. But essentially flat for years (a ~1.7% bump off $1.20), i.e., minimal dividend growth — an income holding, not a dividend grower.

The insider tell (soft-negative). Across 96 Form 4 filings in 2024–2026, there were zero code-P open-market purchases — only routine RSU/LTIP grants, tax withholdings, and a single sale. Insider ownership is thin (all 17 directors/officers hold ~1.63M shares, <1%; the register is index-dominated — Vanguard ~13%, BlackRock ~10%). So the same management arguing publicly that the stock is below NAV, and buying it back with corporate cash, chose not to buy a single personal share. That is a neutral-to-soft signal that undercuts the conviction of the corporate buyback.

Incentive alignment (proxy): Annual bonus is 55% Normalized FFO/share + 15% net debt/EBITDAre — the right REIT levers, though FFO/share can be gamed via leverage. LTIP is 60% relative TSR (vs. healthcare-REIT and comp peers) + 40% service with an FFO/share hurdle; encouragingly, the 2023 LTIP paid below target on relative TSR — pay-for-performance is actually biting. No absolute-return hurdle, though.

Verdict: Management has allocated capital intelligently — the sell-high/buy-back-cheap recycling and the Janus multiple-arbitrage are genuinely shareholder-friendly and NAV-accretive. The asterisks: near-term FFO-dilutive, dependent on a persistent JAN premium, related-party governance hair, and no insider willing to buy alongside the corporate bid.

8. Changes and Headwinds — Last Two Years

Strategic changes:

• March 2024: Closed the all-stock Physicians Realty merger — transformational, roughly doubling the outpatient platform to ~40M sf and internalizing property management. Synergies now exceed $65M (vs. a $60M year-two target), and the MOB platform is performing at/above merger underwriting (+3.8% same-store NOI, 92% occupancy).
• March 2026: Janus Living IPO (see §7) — the year’s defining capital-markets event.
• Dec 2025–Jan 2026: ~$925M transaction package, including the Gateway South SF campus (~$559M) and buying in the remaining 46.5% of the SWF senior-housing JV to 100% (~$312M).
• March 2026: Blackstone outpatient JV recap ($163M net, $92M non-recurring gain); $400M 2031 delayed-draw term loan (undrawn dry powder).
• April 2025: Switched to a monthly dividend and modestly raised it to $1.22.

Headwinds:

• Lab downturn (the big one): same-store lab NOI +5.0% → −7.2% in five quarters, same-store occupancy ~98% → ~90%, against ~23% national vacancy, a supply glut, and the July-2026 NIH funding cut.
• Rising cost of debt: DOC refinanced ~$800M of 3.4–4.0% maturities in 2025 with ~$1.0B of 4.75–5.375% notes, and ~$650M of 3.5% notes mature in June 2026 — a structural FFO headwind driving part of the 2026 decline.
• Disposition dilution: selling at 6% caps is NAV-accretive but FFO/share-dilutive in the near term.
• Janus minority leakage: 18.4% of senior-housing earnings now accrues to outside holders.
• Sell-side caution: Morgan Stanley downgraded to Equal-Weight (June 2026) on valuation after the rally (while raising its price target).

Verdict: The merger strengthened the thesis (a bigger, better outpatient annuity); the lab downturn and debt-cost reset weakened the near-term earnings trajectory; the Janus IPO is a wash-to-positive (value revelation offset by governance friction and near-term neutrality). Net: a thesis in transition, with the balance hinging on the lab trough.

9. Risk Analysis (Risk Matrix)

The dominant risks are not balance-sheet risks — leverage and liquidity are comfortable and investment-grade. The dominant risks are earnings-trajectory risks: a deeper/longer lab trough, a rate backup that hits a −0.53-InterestRate-beta name, and a JAN de-rating that collapses the arbitrage DOC still owns 81.6% of. There is no realistic catastrophic-loss scenario here (diversified, IG, hard-asset backed); the realistic bad case is multi-year dead money if lab stays broken and rates stay high.

10. Valuation Discussion (Embedded Expectations)

Where it trades. At $21.65, DOC is ~12.5x 2026E FFO-adjusted ($1.73 mid), ~11.8x 2025 FFO-adjusted, ~1.9x tangible book (~$10.89/sh, which understates NAV since real estate is carried at depreciated cost), ~5.6% dividend yield, and a ~6.5–7% implied cap rate on gross assets. AZI’s own-history percentile screen puts DOC’s composite valuation at the ~80th percentile (P/S ~83rd, P/B ~67th; ignore the 90th-percentile P/E, which is GAAP-distorted) — i.e., after the 37% rally, DOC is at the richer end of its own recent multiple range, even as it remains cheap versus higher-quality healthcare-REIT peers.

The comp set bifurcates cleanly by business model:

DOC sits squarely in the cheap MOB/lab cohort (HR, ARE) rather than the premium SHOP cohort (WELL, VTR). That is correct, not an anomaly: 89% of DOC’s NOI is outpatient + lab, the two lower-multiple property types.

Embedded expectations / what the market is underwriting. At ~12.5x forward FFO with earnings declining ~6% this year, the market is pricing DOC as a stable-but-no-growth diversified landlord with a broken lab leg — essentially a bond-plus with a ~5.6% coupon and a modest lab-recovery call option. It is not pricing a lab recovery (that would compress the multiple gap to WELL/VTR), and it is only partially crediting the Janus premium (the JAN stake alone, marked at ~$5.7B, is ~38% of DOC’s ~$15B equity cap).

Sum-of-the-parts (illustrative, skeptical). Walk the arithmetic. DOC’s common equity is marked at ~$15.0B ($21.65 × ~695M shares). Its 81.6% stake in Janus Living carries a public mark of ~$5.7B. Subtract that and the market is valuing the stub — the outpatient platform plus the lab franchise, net of the debt not associated with Janus — at only ~$9.3B. Against ~$1.36B of combined outpatient + lab NOI, that stub trades at a high-single-digit implied cap rate, i.e., cheaper than the ~6.1% cap rate at which DOC is selling stabilized outpatient assets to Blackstone. On its face, that is a real dislocation: the private market pays ~6% caps for the outpatient buildings the public is valuing at ~8–9%.

But three haircuts temper the “hidden value” case. First, the JAN mark is a three-week-old IPO sentiment premium (~25–30x AFFO) with no track record; value it at senior-housing-peer multiples nearer 18–20x and DOC’s stake is worth closer to ~$4.0–4.5B, widening the stub to ~$10.5–11.0B and shrinking the discount. Second, the lab component of the stub is deteriorating (−7.2% same-store NOI), so a blended stub cap rate mixes a healthy outpatient annuity with an impaired lab book — the “cheap” stub is cheap partly because a third of it is shrinking. Third, DOC’s leverage sits at the stub level, so small changes in the assumed debt allocation swing the stub equity materially. The honest read: DOC is trading around, to modestly below, a defensible NAV. There is a genuine SOTP argument that the crown-jewel outpatient platform is under-credited — but it is not the table-pounding 30–40% discount the raw JAN-stake subtraction implies, and it is only monetizable if the JAN premium holds and lab stops bleeding.

Scenario framing (FFO-multiple based, no price target):

• Bear: lab SS NOI stays negative into 2027, rates back up, JAN de-rates → FFO stagnates near $1.70 and the multiple compresses toward ~10x; the stock retraces toward its 52-week low.
• Base: lab troughs and slowly inflects, MOB compounds ~3%, JAN premium holds → FFO recovers toward ~$1.80–1.90 by 2027–28 at ~12–13x; a total return driven mostly by the ~5.6% yield.
• Bull: lab occupancy inflects on reopened biotech funding, the 2.5M sf leases up, JAN premium persists and funds accretive M&A → FFO visible toward ~$2.00+ and the multiple re-rates toward the mid-teens.

No price target. No recommendation in this section — see the Author’s Take for a labeled view.

11. Variant Perception

Consensus. DOC is a cheap, diversified, investment-grade healthcare REIT with a well-run outpatient platform, a problematic-but-bottoming lab book, and a clever Janus monetization — fairly valued after a strong 2026 recovery (the modal sell-side stance, e.g., Morgan Stanley’s June-2026 Equal-Weight-on-valuation downgrade).

Strongest bull case. The market is anchored on the lab drag and missing an inflection. Life-science supply has stopped growing, biotech issuance is reopening (April 2026 the strongest since early 2021), and DOC’s ~2.5M sf of vacant lab is latent earnings that converts to NOI as it leases — turning 37% of the portfolio from headwind to tailwind into 2027–28. Layer on a well-run 92%-occupied MOB annuity, a demographic-tailwind senior-housing stake carried at a 30x public multiple, disciplined sell-at-6%/buy-stock-at-10% recycling, and a −0.53 InterestRate beta that makes DOC a leveraged winner if the Fed cuts — and a ~$2.00 FFO number re-rating toward the mid-teens is plausible. You are paid ~5.6% to wait.

Strongest bear case. DOC is a no-moat conglomerate whose 37%-of-NOI lab leg is still deteriorating (SS NOI −7.2% and falling, occupancy through 90%), into a market with 23% vacancy and a fresh ~$18B NIH cut, while its cost of debt resets structurally higher and 2026 FFO/share declines ~6%. The Janus “value creation” is a sentiment-dependent multiple trick DOC owns 81.6% of the downside to; strip the fresh IPO premium and the SOTP discount evaporates. Dividend growth is nil, insiders won’t buy a share, and the stock has already rallied 37% — the easy re-rating is done, and a rate backup or lab air-pocket sends it back toward $16.

The 3–5 assumptions that matter most:

1. Does lab occupancy inflect in 2026–27? (Bull needs net absorption to confirm; bear needs it to keep falling.)
2. Do long rates fall? (The −0.53 InterestRate beta makes this the single biggest exogenous swing.)
3. Does the JAN premium persist? (The entire “hidden value” and SOTP case rests on ~25–30x AFFO holding.)
4. Does biotech funding durably reopen? (The leading indicator for lab demand and rents.)
5. Is management’s NAV view right — and if so, why won’t insiders buy personally?

Factor-positioning read (from the momentum/factor work). The tape confirms the bear’s “already rallied” caution and the bull’s “value” thesis simultaneously: DOC screens as a value / anti-growth / rate-recovery name (Value +0.20, Growth −0.40, Quality −0.18, InterestRate −0.53) with negative momentum-factor loading (−0.16) despite a +197%-annualized three-month price move — i.e., the bounce is mean-reversion off a washed-out base, not a durable momentum trade, and it is highly geared to the rate path. Consensus is not obviously offsides in either direction; this is a genuinely two-sided, macro-levered setup, which is why the honest verdict is HOLD.

12. Fact vs. Interpretation Table

13. Open Questions

1. Exact reconciliation of “77.7% lab occupancy” (Q1’26 call) vs. ~90% same-store lab occupancy (10-K). The 77.7% almost certainly reflects the total in-service portfolio including recently delivered developments in lease-up (the ~2.5M sf of latent earnings); needs confirmation against the supplemental.
2. What multiple will JAN actually hold? The entire hidden-value/SOTP case rests on a freshly-IPO’d ~25–30x AFFO premium that has no track record.
3. 2027 lab lease expirations and renewal rate. Management guides “50% or better” renewal in 2027 vs. worse in 2026 — critical to the inflection call, but early.
4. Why no insider buying if management genuinely believes the stock is below NAV and is buying it back corporately?
5. Post-Janus dividend policy and segment NOI mix — how the 18.4% NCI and consolidation reshape DOC-attributable AFFO and coverage.
6. NIH-cut pass-through — how much of the ~$18B FY26 NIH reduction flows to DOC’s specific tenant base (venture/pharma-weighted vs. academic).

14. What Must Be True

Bull case — what must be true, and its falsification test:

• Claim: Lab troughs in 2026 and inflects to positive same-store NOI by 2027, converting ~2.5M sf of vacancy into earnings, while MOB compounds ~3%, JAN holds its premium, and rates fall.
• Falsification test: If same-store lab NOI is still negative and lab occupancy is below ~88% at year-end 2026 (i.e., net absorption failed to materialize despite the signed-but-not-commenced pipeline), the inflection thesis is broken and DOC is a value trap with a structurally impaired 37% of NOI.

Bear case — what must be true, and its falsification test:

• Claim: The lab downturn is structural (not merely cyclical), the JAN premium is a mirage that de-rates, rates stay high, and DOC is a no-growth conglomerate that already re-rated — dead money at best.
• Falsification test: If DOC posts positive blended same-store NOI and raises 2026 FFO guidance again on lab net absorption, while JAN sustains a >20x AFFO multiple through 2026, the “broken/over-rated” bear thesis is falsified and the stub is demonstrably undervalued.

The single cleanest swing variable is lab same-store NOI direction, closely followed by the long-rate path (given the −0.53 InterestRate beta). Both are trackable quarterly.

15. Source Appendix

See the separate DOC_source_appendix.md (Appendix B in the combined report) for the full, itemized source list with URLs and access dates. Primary sources: Healthpeak FY2025 Form 10-K, Q1 2026 Form 10-Q, 2026 DEF 14A proxy, Q1 2026 and Q4 2025 earnings calls and 8-Ks, and the Janus Living (NYSE: JAN) IPO 424B4/8-K (SEC EDGAR CIK 0002100805). Quantitative data cross-checked via ROIC.ai (financials/ratios/EV), AZI (price history, own-history valuation percentiles, news), and FactorsToday (factor loadings, risk-adjusted track record). Industry data: CBRE, JLL, NIC, Nareit, and trade press as cited in the body. Peer context cross-read from prior internal reports on Ventas (VTR) and Welltower (WELL).

APPENDIX A — Standard Diligence Questionnaire

Healthpeak Properties, Inc. (NYSE: DOC) · As of 2026-07-11 · Supplemental to the research memo (not counted toward memo length). Fact / Interpretation / Assumption labels applied where material.

General

What thoughtful questions have other investors asked about this company? The recurring institutional questions cluster on: (1) Is the life-science trough behind them, and when does lab same-store NOI turn positive? (2) Is the Janus Living IPO genuine value creation or a sentiment-dependent multiple trick, and what does DOC do if JAN de-rates? (3) How dilutive is the disposition/recycling program to near-term FFO, and is it worth the NAV accretion? (4) Why is 2026 FFO/share guided down, and is that the bottom? (5) With the CEO calling the stock cheap and buying it back, why aren’t insiders buying personally? These map directly to the memo’s Open Questions (§13) and What-Must-Be-True (§14).

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? (Interpretation) Mixed and rotating: outpatient at a mid-cycle steady state (~92% occupancy, record MOB fundamentals sector-wide), lab near a cyclical low (same-store NOI −7.2%, occupancy falling), senior housing recovering off a post-COVID low toward mid-cycle. Blended, 2026 FFO/share is a modest trough-ish year (guided down ~6%), pressured by lab and higher refinancing cost.

Driven by external environment or internal actions? Both. External: interest rates (−0.53 factor beta), biotech funding cycle, NIH policy, senior-housing demographics. Internal: the merger synergies, the recycling/buyback program, and the Janus IPO.

How stable are revenues? (Fact) High underlying stability — predominantly triple-net/net leases (72% of MOB, 89% of lab) with ~3% escalators and creditworthy health-system tenants — but occupancy in lab is the swing factor eroding the top line at the margin.

Outlook for products/services; how big is the market? Outpatient and senior-housing end-markets are secular growers (aging demographics; 80+ population +55% by 2035). Lab is a large but currently oversupplied market bottoming on the supply side. Domestic (U.S.-only).

Business Quality & Competitive Moat

Is the industry getting more or less competitive? (Interpretation) Outpatient: less competitive (supply discipline, record occupancy). Lab: more stressed near-term (23% vacancy), but new supply is collapsing. Senior housing: capital is flooding back (~$24B/yr), compressing cap rates.

How profitable is the business (ROIC, ROE)? GAAP ROIC/ROE are not meaningful for a REIT (depreciation distortion). The economic returns: ~6.5–7% implied cap rate on gross assets, ~10%+ AFFO yield at the current stock price, ~55% EBITDA margin. (Fact)

How profitable is the industry; barriers to entry? Moderate. Barriers: capital intensity, health-system relationships (MOB), specialized wet-lab construction, entitlement/zoning. Not high enough to prevent the 2020–21 lab oversupply.

Can the business be easily understood? Yes for MOB and senior housing; lab requires understanding the biotech funding cycle. Overall a comprehensible hard-asset landlord.

Undermined by foreign low-cost labor? No — domestic real estate.

Do brands matter? Nature of competition? Switching costs? Brand matters little; relationships and location matter greatly. On-campus MOB and premier-cluster lab create genuine switching costs (a hospital’s physicians, or a lab tenant’s specialized build-out, are costly to relocate). Competition is on cost of capital, submarket dominance, and operating platform quality.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? (Interpretation) Yes — real estate is carried at depreciated cost, so tangible book (~$10.89/sh) understates NAV; the ~2.5M sf of vacant lab is latent (currently non-earning) value; and the JAN stake now carries a public mark (~$5.7B) above its ~$3B book.

Off-balance-sheet liabilities? JV/unconsolidated obligations (Blackstone OM JV, others) are modest and disclosed; no unusual off-balance-sheet leverage. Ground leases and JV guarantees are standard.

How conservative is the accounting? (Interpretation) Above-average for the sector — minimal straight-line-rent build (~6% of FFO non-cash), AFFO ~92% of FFO-adjusted, clean AFFO bridge. Non-recurring gains ($92M Blackstone, $46M SWF) are separately identifiable.

How CapEx-hungry? Moderately. Recurring/second-gen AFFO capex ~$134M (~10% of FFO); plus development/redevelopment (~$168M committed) and opportunistic acquisitions. Lower TI/LC intensity in MOB than peers is a genuine edge.

Capital Allocation & Management

How much FCF, and how is it used? (Fact) ~$1.25B operating cash flow (FY25) funds ~$849M dividends (~72% AFFO payout) with the balance to capex, buybacks (~$100M in Apr-26), and debt service. Philosophy: sell stabilized assets at tight caps, recycle into buybacks (at ~10% AFFO yield) and distressed acquisitions.

Significant acquisitions recently? Gateway South SF (~$559M), SWF senior-housing buy-in (~$312M), Mar-26 senior housing (~$402M); the Physicians Realty merger (2024).

Buying back shares? Yes — ~$94M (2025) + ~$100M (Apr-26), ~$306M remaining authorization; NAV-accretive.

Issuing large amounts of stock to insiders? SBC is small (~$14–32M/yr). Insider ownership is thin (<1%). No excessive dilution.

Compensation policy / motivations of management? (Fact) Bonus 55% FFO/share + 15% net debt/EBITDAre; LTIP 60% relative TSR + 40% service (FFO/share hurdle); 2023 LTIP paid below target — pay-for-performance is biting. CEO Scott Brinker (ex-Welltower CIO); CFO Kelvin Moses (promoted Apr-25). (Interpretation) Alignment is decent on metrics but weak on personal ownership/skin-in-the-game.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — a U.S. C-corp-form REIT; issues a 1099-DIV (not a K-1). No ADR/MLP complexity.

Dividend policy? $1.22/share annual, paid monthly (since Apr-25), ~5.6% yield, ~72% AFFO payout — well-covered but essentially flat for years (minimal growth).

How profitable is the business? See above — economic returns are landlord-typical (~6.5–7% asset yields); the equity’s ~10% AFFO yield reflects the depressed multiple.

Is net income diverging from cash from operations? (Fact) Yes, and appropriately — GAAP net income ($71M FY25) is a fraction of ~$1.25B operating cash flow because of ~$1.06B real-estate depreciation. This is normal REIT mechanics, not a red flag.

Risks & Downside

What factors would cause the stock to decline? A deeper/longer lab trough (SS NOI staying negative), a backup in long rates (−0.53 InterestRate beta), a JAN de-rating collapsing the SOTP premium, or continued FFO/share declines. See Risk Matrix (§9).

Risk of catastrophic loss? (Interpretation) Low. Diversified, investment-grade (Baa1/BBB+), hard-asset-backed, 88% fixed-rate debt, $3.0B undrawn revolver. No realistic wipeout scenario; the realistic bad case is multi-year dead money.

Chance of a total loss? Negligible — this is a diversified IG landlord, not a single-asset or going-concern situation.

Recent News & Events

Has the business environment changed recently? (Fact) Yes: the March-2026 Janus Living IPO (defining event); the July-2026 NIH funding cut (~$18B); the biotech funding reopening (April 2026 strongest issuance since early 2021); and the ~$650M June-2026 debt refinancing at higher coupons.

Significant acquisitions/divestitures? Gateway South SF acquisition; Blackstone OM JV recap (disposition of 80% of six buildings at 6.1% cap); 2025 outpatient dispositions (~$346M); Physicians Realty merger (2024).

Change in accounting policies? None material; Janus consolidation with 18.4% NCI is the notable structural change.

Recent changes — new markets, facilities, management? Janus external-management platform stood up; CFO transition (Moses promoted Apr-25); expanded South SF footprint; monthly dividend adopted.

APPENDIX B — Source Appendix

Healthpeak Properties, Inc. (NYSE: DOC) · Research as of 2026-07-11. Primary sources first. Fact / Interpretation separation is maintained in the memo body; this appendix lists the evidentiary base.

Primary — SEC filings (EDGAR CIK 0000765880; files as “peak”)

1. Form 10-K, FY2025 — Healthpeak Properties, filed Feb 2026. Segment NOI, same-store schedules, debt footnote, tenant concentration, risk factors. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000765880&type=10-K
2. Form 10-Q, Q1 2026 — filed 2026-05-06 (peak-20260331.htm). FFO/AFFO, Q1 same-store NOI, Janus Living consolidation (Notes 1/11/18/20), $92M Blackstone deconsolidation gain, term-loan details. https://www.sec.gov/Archives/edgar/data/765880/000162828026031287/peak-20260331.htm
3. DEF 14A proxy — filed 2026-03-12. Executive comp structure (STIP 55% FFO/sh + 15% ND/EBITDAre; LTIP 60% rel-TSR), 2023 LTIP below-target payout, insider ownership, company-reported FFO/FFO-adj/AFFO per share. https://www.sec.gov/Archives/edgar/data/765880/000110465926027086/doc-20260430xdef14a.htm
4. Form 8-K, 2026-05-05 / 2026-05-04 — Q1 2026 earnings release and supplemental; 2026 FFO-adj guidance raise to $1.71–$1.75.
5. Form 8-K, 2026-03-23 — Janus Living IPO closing / Blackstone JV / term-loan financings.
6. Form 4 corpus (2024–2026, 96 filings) — insider transactions; scanned for code-P open-market purchases (found: zero). EDGAR insider feed for CIK 0000765880.
7. Janus Living, Inc. (NYSE: JAN) — 424B4 / Form 8-K — IPO prospectus and closing, SEC EDGAR CIK 0002100805. 48.3M shares at $20.00; DOC 81.6% retained; external-management agreement.
8. Prior 10-Ks / 10-Qs (2021–2024) — trailing 60-month corpus (mirrored locally) for multi-year revenue, NOI, debt, and merger integration history.

Primary — earnings calls / management commentary

9. Q1 2026 earnings call (2026-05-06) — CEO Scott Brinker / CFO Kelvin Moses. Lab occupancy 77.7% (total, in-service) and ≥100bps YE target; MOB 5.4% re-leasing spreads, 91% occupancy; Gateway South SF; Blackstone JV 6.1% cap; $100M April buyback at >10% FFO yield; Janus $240M FFO valued ~20 turns higher. (ROIC.ai transcript.)
10. Q4 2025 earnings call (2026-02-03) — FY2025 results, 2026 initial guidance, Janus IPO progress. (ROIC.ai transcript.)

Quantitative cross-checks (third-party aggregated — reconciled to filings)

11. ROIC.ai MCP — income statement, balance sheet, cash flow, profitability/credit/yield ratios, enterprise value (~$21.7B at 12/31/25 price; ~$24.5B at current), valuation multiples, per-share data (tangible book ~$10.89/sh). Accessed 2026-07-11.
12. AZI (azitrading.com) — 5-year adjusted price CSV (peak $37.36 Aug-2021; low $15.55 Oct-2023; $21.65 on 2026-07-10); own-history valuation percentiles (composite ~80th; P/S ~83rd; P/B ~67th); news feed (Morgan Stanley Equal-Weight downgrade, 2026-06-11). Accessed 2026-07-10/11.
13. FactorsToday (factorstoday.com/api) — factor loadings (InterestRate −0.53, Value +0.20, Growth −0.40, Quality −0.18, Momentum −0.16; Sector Real Estate +1.10, Market +0.88); leaderboard (m3 +197% annualized, y5 −1.3%, beta 0.62); related-stocks (HR closest, 0.94 similarity). Accessed 2026-07-09/10.

Industry / sector data

14. CBRE — Q1 2026 U.S. Life Sciences Figures — national lab vacancy ~23.3%, oversupply metrics. https://www.cbre.com/insights/figures/q1-2026-us-life-sciences-figures
15. JLL — 2026 Medical Outpatient Building Perspective — MOB occupancy record ~92.7%, lowest new supply in ~two decades. https://www.jll.com/en-us/insights
16. NIC (National Investment Center) — senior-housing occupancy ~89.5%, record-low inventory growth (+0.4%). https://www.nic.org
17. Boston Real Estate Times / trade press — Boston lab vacancy and sub-$80/sf asking rents (2026). https://bostonrealestatetimes.com
18. Biospace / policy coverage — One Big Beautiful Bill Act NIH funding cut ~$18B to $27.5B for 2026. https://www.biospace.com
19. Bisnow / Senior Housing News — Janus Living IPO launch and DOC senior-housing re-entry (Jan–Mar 2026). https://www.bisnow.com · https://seniorhousingnews.com
20. Nareit — Physicians Realty merger synergies (>$65M) and healthcare-REIT context. https://www.reit.com

Peer context

21. Ventas (VTR) and Welltower (WELL) — public healthcare-REIT peers referenced for industry framing, senior-housing dynamics, and comparative valuation; all underlying facts independently sourced from public filings and data.

ROIC.ai, AZI, and FactorsToday are third-party aggregated data, not primary sources; for U.S. filers, EDGAR filings are authoritative and every material figure driving a verdict was reconciled to the filing. No figure from any aggregator or analyst was used as a price target (none appears in the memo body).